Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

References

• Hodgkin Lymphoma Cancer stat facts; [cited 2022 February 10]. Available from: https://seer.cancer.gov/statfacts/html/ hodg.html
   Google Scholar
• Hodgkin Lymphoma. NCCN clinical practice guidelines in oncology (NCCN guidelines ®) NCCN.org NCCN guidelines for patients ®; 2021. Available from: www.nccn.org/patients. Accessed February 2, 2022.
   Google Scholar
• van Leeuwen FE, Ng AK. Late sequelae in Hodgkin lymphoma survivors. Hematol Oncol. 2017;35:60–66. doi:10.1002/hon.2402
   PubMed Web of Science ®Google Scholar
• van Nimwegen FA, Ntentas G, Darby SC. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257–2265. doi:10.1182/blood-2016-09-740332
   PubMed Web of Science ®Google Scholar
• Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378(4):331–344. doi:10.1056/NEJMoa1708984
   PubMed Web of Science ®Google Scholar
• Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e410–e421. doi:10.1016/S2352-3026(21)00102-2
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Hamlin P, Kewalramani T, et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2003;14(SUPPL. 1):i5–i10. doi:10.1093/annonc/mdg702
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Niedzwiecki D, Johnson JL, et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18(6):1071–1079. doi:10.1093/annonc/mdm090
   PubMed Web of Science ®Google Scholar
• Castagna L, Santoro A, Carlo-Stella C. Salvage therapy for Hodgkin’s lymphoma: a review of current regimens and outcomes. J Blood Med. 2020;11:389–403. doi:10.2147/JBM.S250581
   PubMed Web of Science ®Google Scholar
• Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–3473. doi:10.1158/1078-0432.CCR-13-0855
   PubMed Web of Science ®Google Scholar
• Cader FZ, Schackmann RCJ, Hu X, et al. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018;132(8):825–836. doi:10.1182/blood-2018-04-843714
   PubMed Web of Science ®Google Scholar
• Carey CD, Gusenleitner D, Lipschitz M, et al. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017;130(22):2420–2430. doi:10.1182/blood-2017-03-770719
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690–2697. doi:10.1200/JCO.2016.66.4482
   PubMed Web of Science ®Google Scholar
• Wienand K, Chapuy B, Stewart C, et al. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019;3(23):4065–4080. doi:10.1182/bloodadvances.2019001012
   PubMed Web of Science ®Google Scholar
• Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2015;13(1):25–40. doi:10.1038/nrclinonc.2015.187
   PubMed Web of Science ®Google Scholar
• Pezeshki PS, Eskian M, Hamblin MR, Rezaei N. Immune checkpoint inhibition in classical Hodgkin lymphoma. Expert Rev Anticancer Ther. 2021;00(00):1–14.
   Google Scholar
• Al-Hadidi SA, Chuang HH, Miranda RN, Lee HJ. Programmed cell death-one inhibition therapy in classical Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(2):e105–e111. doi:10.1016/j.clml.2020.08.031
   PubMed Web of Science ®Google Scholar
• Savage KJ, Steidl C. Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. Expert Rev Hematol. 2016;9(11):1007–1009. doi:10.1080/17474086.2016.1242404
   PubMed Web of Science ®Google Scholar
• Lin RJ, Diefenbach CS. Checkpoint inhibition in Hodgkin lymphoma: saving the best for last? Oncology (Williston Park). 2016;30(10):914–920.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Maruyama D, Hatake K, Kinoshita T, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci. 2017;108(5):1007–1012. doi:10.1111/cas.13230
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294. doi:10.1016/S1470-2045(16)30167-X
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34(31):3733–3739. doi:10.1200/JCO.2016.67.3467
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132. doi:10.1200/JCO.2016.72.1316
   PubMed Web of Science ®Google Scholar
• Armand P, Zinzani PLL, Lee HJ, et al. Five-year follow-up of keynote-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). Blood. 2021;138(Supplement 1):1366. doi:10.1182/blood-2021-147881
   Web of Science ®Google Scholar
• Armand P, Kuruvilla J, Michot JM, et al. KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure. Blood Adv. 2020;4(12):2617–2622. doi:10.1182/bloodadvances.2019001367
   PubMed Web of Science ®Google Scholar
• Herrera AF, Chen L, Popplewell LL, et al. Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma. Blood. 2019;134(Supplement_1):759. doi:10.1182/blood-2019-123163
   Web of Science ®Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–2409. doi:10.1182/blood.2019004701
   PubMed Web of Science ®Google Scholar
• Armand P, Bin CY, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019;134(1):22–29. doi:10.1182/blood.2019000215
   PubMed Web of Science ®Google Scholar
• Bachier C, Schade H, Zoghi B, Ramakrishnan A, Shah NN. A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression. Blood. 2021;138(Supplement 1):2455. doi:10.1182/blood-2021-148139
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194. doi:10.1182/blood-2017-10-811224
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Advani RH, Bartlett NL, et al. Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1/2 study. Blood. 2019;134(Supplement_1):238. doi:10.1182/blood-2019-122576
   Web of Science ®Google Scholar
• Bryan LJ, Smith SE, Allen P, et al. Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment. Blood. 2019;134(Supplement_1):4029. doi:10.1182/blood-2019-123879
   Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. KEYNOTE-204: randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). ASCO Ann Meet. 2020;38(15_suppl):8005. doi:10.1200/JCO.2020.38.15_suppl.8005
   Google Scholar
• Moskowitz AJ, Shah G, Schöder H, et al. Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol. 2021;39:3109–3117. doi:10.1200/JCO.21.01056
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e670. doi:10.1016/S2352-3026(20)30221-0
   PubMed Web of Science ®Google Scholar
• Patel SS, Weirather JL, Lipschitz M, et al. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative. Blood. 2019;134(23):2059–2069. doi:10.1182/blood.2019002206
   PubMed Web of Science ®Google Scholar
• Alencar AJ, Moskowitz CH. Immune-checkpoint inhibition as first-line therapy for Hodgkin lymphoma. Nat Rev Clin Oncol. 2019;16(10):599–600. doi:10.1038/s41571-019-0255-8
   PubMed Web of Science ®Google Scholar
• Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma. Blood. 2021;137(10):1318–1326. doi:10.1182/blood.2020007400
   PubMed Web of Science ®Google Scholar
• Bröckelmann PJ, Goergen H, Keller U. Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial. JAMA Oncol. 2020;6(6):872–880. doi:10.1001/jamaoncol.2020.0750
   PubMed Web of Science ®Google Scholar
• Ramchandren R, Fanale MA, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 checkmate 205 study. Blood. 2017;130(Suppl 1):651. doi:10.1182/blood.V130.Suppl_1.651.651
   Google Scholar
• Ansell S, Ramchandren R, Domingo-Domènech E, et al. Nivolumab plus doxorubicin, vinblastine and dacarbazine for newly diagnosed advanced-stage classical Hodgkin lymphoma: checkmate 205 cohort D 2-year follow-up. Hematol Oncol. 2019;37:146–147. doi:10.1002/hon.104_2629
   Google Scholar
• Ramchandren R, Domingo-Domènech E, Rueda A. Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II checkMate 205 study. J Clin Oncol. 2019;37(23):1997–2007. doi:10.1200/JCO.19.00315
   PubMed Web of Science ®Google Scholar
• Roemer MGM, Redd RA, Cader FZ, et al. Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018;36(10):942–950. doi:10.1200/JCO.2017.77.3994
   PubMed Web of Science ®Google Scholar
• Shi Y, Su H, Song Y, et al. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2019;6(1):e12–e19. doi:10.1016/S2352-3026(18)30192-3
   PubMed Web of Science ®Google Scholar
• Song Y, Gao Q, Zhang H. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020;34(2):533–542. doi:10.1038/s41375-019-0545-2
   PubMed Web of Science ®Google Scholar
• Song Y, Wu J, Chen X. A single-arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma. Clin Cancer Res. 2019;25(24):7363–7369. doi:10.1158/1078-0432.CCR-19-1680
   PubMed Web of Science ®Google Scholar
• Nie J, Wang C, Liu Y, et al. Addition of low-dose decitabine to anti–PD-1 antibody camrelizumab in relapsed/refractory classical Hodgkin lymphoma. J Clin Oncol. 2019;37(17):1479–1489. doi:10.1200/JCO.18.02151
   PubMed Web of Science ®Google Scholar
• Herrera AF, Burton C, Radford J, et al. Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood Adv. 2021;5(17):3387–3396. doi:10.1182/bloodadvances.2021004511
   PubMed Web of Science ®Google Scholar
• Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010;116(17):3268–3277. doi:10.1182/blood-2010-05-282780
   PubMed Web of Science ®Google Scholar
• Cader FZ, Hu X, Goh WL, et al. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020;26(9):1468–1479. doi:10.1038/s41591-020-1006-1
   PubMed Web of Science ®Google Scholar